Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq.The South San Francisco start-up – led by former MSD head of R&D Roger Perlmutter – sold 21.2 million shares in the company at $18 […]
